

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Ye, et al.

Appl. No.: 10/755,854

Filed: January 13, 2004

For: Eosinophil-Derived Neurotoxin as a

Marker for Ovarian Cancer

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7570/80962

Supplemental Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
220 20th Street South
Customer Window, **MS Amendment**Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed document are also enclosed with the exception of the United States patents.

Applicants also wish to make the Examiner aware of co-pending applications 09/948,094, filed September 7, 2001; 10/162,221, filed on June 5, 2002; and 10/869,027, filed on June 17, 2004.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.



Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicants do not believe any fees are due for the submission of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Mulail A. Say Michael A. Sanzo Reg. No. 36,912

Attorney for Applicants

Date August 12 , 2004

1801 K Street, N.W., Suite 401L Washington, DC 20006-1201

Phone: (202) 419-7013



Atty. Docket No.: 7570/80962

Appl. No.: 10/755,854

Applicant(s)


Ye, et al.

Filing Date: January 13, 2004

Group: to be assigned

U.S. PATENT DOCUMENT	S	
----------------------	---	--

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A 1	5,604,106	Feb. 18, 1997	Liotta, et al.	435	7.23	May 18, 1993
	A 2	5,695,761	Dec. 9, 1997	Denhardt, et al.	424	184.1	Dec. 23, 1993
	A 3	5,712,104	Jan. 27, 1998	Yamamoto	435	7.92	Jan. 6, 1997
	A 4	5,801,004	Sep. 1, 1998	Hudson, et al.	435	7.23	Dec. 23, 1996
	A 5	6,414,219 B1	Jul. 2, 2002	Denhardt, et al.	800	18	Jun. 30, 1999
	A 6	6,686,444 B2	Feb. 3, 2004	Ashkar	530	329	Aug. 21, 1997
	A 7	2002/0039753 A1	Apr. 4, 2002	Chai, et al.	435	7.23	Jan. 5, 2001
	A 8	2002/0052308 A1	May 2, 2002	Rosen, et al.	514	1	Aug. 10, 2001
	A 9				ļ		
	A 10						
	A 11						
	A 12						
	A 13						
	A 14						
	A 15						
	A 16				ļ <u>.</u>	·	
	A 17				<u> </u>		
	A 18		: 				
	A 19		New Control of the Co				
	A 20				ļ		
	A 21						
	A 22						
	A 23						
	A 24						
	A 25				ļ		
	A 26						
	A 27				<u>L</u>		
Examiner		· · ·		Date Considered			




Atty. Docket No.: 7570/80962 Appl. No.: 10/755,854

Applicant(s) Ye, et al.

Filing Date: January 13, 2004 Group: to be assigned

FOREIGN PATENT DOCUMENTS

							Abst./Trans.	
Examiner Initial		Document Number	Date	Country	Class	Subclass	Yes	No
	B 1							<u> </u>
	B 2							
	В 3							
	B 4							_
	B 5							_
	В 6							
	В7							<u> </u>
	В 8							ļ
· · · · · · · · · · · · · · · · · · ·	В9							
	B 10							
	B 11							
	B 12							ļ
	B 13							
	B 14							
	B 15					ļ		<u> </u>
	B 16							
	B 17					<u></u>		$oldsymbol{ol}}}}}}}}}}}}}}$
	B 18							
	B 19							<u> </u>
	B 20							<u> </u>
	B 21							$oldsymbol{ol}}}}}}}}}}}}}}}}}}$
	B 22							ļ
	В 23							_
	B 24							
	В 25							<u> </u>
	B 26							
	B 27							
Examiner				Date Considered				



Atty. Docket No.: 7570/80962 Appl. No.: 10/755,854

Applicant(s) Ye, et al.

Filing Date: January 13, 2004 Group: to be assigned

Examiner Initial		OTHER PRIOR ART (Includ	ing Author, Title, Date, Pertinent Pages, Etc.)			
	C 1 BAST, et al., "A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer," N. Engl. J. Med. 309:883-887 (1983).					
	C 2	BERTEAU, et al., "Prostasin mRNA to Detect Prostate Cells in Blood of Cancer Patients," Clin. Chem. Lab. Med. 37:S119 (1999).				
	C 3	CHEN, et al., "Down-Regulation of Prostasin Serine Protease: A Potential Invasion Suppressor in Prostate Cancer," Prostate 48:93-103 (2001).				
	C 4	CHEN, et al., "Prostasin Serine Protease Inhibits Breast Cancer Invasiveness and Is Transcriptionally Regulated by Promoter DNA Methylation," Int. J. Cancer 97:323-329 (2002).				
	C 5	CHEUNG, et al., "Identify Metastasis-Associated Genes in Hepatocellular Carcinoma through Clonality Delineation for Multinodular Tumor," Cancer Res. 62:4711-4721 (2002).				
_	C 6	COOLEN, et al., "Elevation of Brain-Type Creatine Kinase in Serum from Patients with Carcinoma," Cancer 44:1414-1418 (1979).				
	C 7	CRAMER, et al., "Carotenoids, Antioxidants and Ovarian Cancer Risk in Pre- and Postmenopausal Women," Int. J. Cancer 94:128-134 (2001).				
	C 8	DALY, et al., "The Search for Predictive Patterns in Ovarian Cancer: Proteomics Meets Bioinformatics," Cancer Cell 1:111-112 (2002).				
	C 9	DENHARDT, et al., "Osteopontin: A Protein with Diverse Functions," FASEB J. 7:1475-1482 (1993).				
	C 10	DeRISI, et al., "Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer," Nature Genetics 14:457-460 (1996).				
·	C 11	FISH, et al., "Changes in Serum Acute Phase Proteins in Ovarian Cancer Patients Receiving Cis-Diamminedichloro-platinum (CDDP) Infusion Therapy," Clinical Biochem. 17:39-41 (1984).				
	C 12	FISH, et al., "Serum Haptoglobin and α1-Acid Glycoprotein as Indicators of the Effectiveness of cis- Diamminedichloroplatinum (CDDP) in Ovarian Cancer Patients – a Preliminary Report," Eur. J. Cancer Clin. Oncol. 20:625-630 (1984).				
	C 13	GIACHELLI, et al., "Molecular and Cellular Biology of Osteopontin," Trends Cardiovasc. Med. 5:88-95 (1995).				
	C 14	GINGRICH, et al., "Metastatic Prostate Cancer in a Transgenic Mouse," Cancer Res. 56:4096-4102 (1996).				
	C 15	HARVEY, et al., "Cancer Cells Release a Covalent Complex Containing Disulfide-Linked Domains from Urinary Plasminogen Activator, Neural Cell Adhesion Molecule, and Haptoglobin α and β Chains," Arch. Biochem. Biophys. 345:289-298 (1997).				
	C 16	HEID, et al., "Real Time Quantitative PCR," Genome Res. 6:986-994 (1996).				
	C 17	HOOPER, et al., "Testisin, a New Human Serine Proteinase Expressed by Premeiotic Testicular Germ Cells and Lost in Testicular Germ Cell Tumors," Cancer Res. 59:3199-3205 (1999).				
	C 18	HOOPER, et al., "Localization, Expression and Genomic Structure of the Gene Encoding the Human Serine Protease Testisin," Biochimica et Biophysica Acta 1492:63-71 (2000).				
	C 19	9 KIBEL, et al., "Loss of Heterozygosity at 12P12-13 in Primary and Metastatic Prostate Adenocarcinoma," J. Urol. 164:192-196 (2000).				
Examiner			Date Considered	•		

			Atty. Docket No.: 7570/80962	Appl. No.: 10/755,854		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)			Applicant(s) Ye, et al.			
•	'	out to the armites y necessary,	Filing Date: January 13, 2004	Group: to be assigned		
Examiner Initial		OTHER PRIOR ART (Incl.	uding Author, Title, Date, Pertinent Pages, Etc.)			
	C 20	KIEFER, et al., "The cDNA and Derived A (1989).	Amino Acid Sequence for Human Osteopo	ontin," Nuc. Ac. Res. 17:3306		
	C 21	KIM, et al., "Osteopontin as a Potential Dia	agnostic Biomarker for Ovarian Cancer,"	JAMA 287:1671-1679 (2002).		
	C 22	KO, et al., "Haptoglobin Typing and Quan Chinese J. Microbiol. Immunol. 13:149-157		iynecologic Cancer Patients,"		
	C 23	KO, et al., "Haptoglobin Typing and Quan Chinese J. Microbiol. Immunol. 13:149-157				
-	C 24	KURTZ, et al., "Serum Creatine Kinase BI Cancer 56:562-566 (1985).	3 Isoenzyme as a Diagnostic Aid in Occul	It Small Cell Lung Cancer,"		
	C 25	MILLS, et al., "Future for Ovarian Cancer Profiling and Proteomics," J. Natl. Cancer.		g Technologies of Transcriptional		
	C 26 MOK, et al., "Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology," J. Natl. Cancer Inst. 93:1458-1464 (2001).					
	C 27	 Gynecologic Oncol. 52:247-252 (1994). MOK, et al., "SPARC, an Extracellular Matrix Protein with Tumor-Suppressing Activity in Human Ovarian Epithe Cells," Oncogene 12:1895-1901 (1996). 				
	C 28					
	C 29					
	C 30	Gly-Asp Cell-Binding Sequence," Proc. Natl. Acad. Sci. USA 83:8819-8823 (1986).				
	C 31					
	C 32	PATARCA, et al., "Differential Induction of Interferon γ Gene Expression after Activation of CD4* Cells by Conventional Antigen and Mls Superantigen," Proc. Natl. Acad. Sci. USA 88:2736-2739 (1991).				
	C 33	PENG, et al., "Proteomics: The Move to M	ixtures," J. Mass Spectrom. 36:1083-1091	(2001).		
	C 34	PETRICOIN, et al., "Use of Proteomic Patt	erns in Serum to Identify Ovarian Cancer	;" Lancet 359:572-577 (2002).		
	C 35	PIVA, et al., "Interleukin-6 Differentially Stimulates Haptoglobin Production by Peritoneal and Endometriotic Cells in Vitro: A Model for Endometrial-Peritoneal Interaction in Endometriosis," J. Clin. Endocrinol. Metab. 86:2553-2561 (2001).				
	C 36	REN, et al., "Reduced Lysyl Oxidase Messenger RNA Levels in Experimental and Human Prostate Cancer," Cancer Res. 58:1285-1290 (1998). SCHNEIDER, et al., "Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer," Clin. Cancer Res. 10:1588-1596 (2004).				
	C 37					
	C 38					
Examiner			Date Considered			

			Atty. Docket No.: 7370/80962	Appl. No.: 10/755,854		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)			Applicant(s) Ye, et al.			
			Filing Date: January 13, 2004	Group: to be assigned		
Examiner Initial		OTHER PRIOR ART (Inc	luding Author, Title, Date, Pertinent Pages, Etc.)			
	C 39	SCHUMMER, et al., "Comparative Hybri Overexpressed in Ovarian Carcinomas," C	dization of an Array of 21 500 Ovarian cDi Gene 238:375-385 (1999).	NAs for the Discovery of Genes		
	C 40	SENGER, et al., "Elevated Expression of Neoplastic Transformation," Anticancer Re	Secreted Phosphoprotein I (Osteopontin, 2a es. 9:1291-1300 (1989).	r) as a Consequence of		
	C 41	SHARP, et al., "Tumor Cells Are the Sour Cancer," Lab. Investig. 79:869-877 (1999)	rce of Osteopontin and Bone Sialoprotein E	xpression in Human Breast		
	C 42		anti-Haptoglobin.Alpha.Chain Antibodies," Caplus, Accession No. 1990:548290, (Sch.			
	C 43	SMITH, et al., "Molecular Cloning of a Tu Induction Is Stable at High, but Not at Lov	umor Promoter-Inducible mRNA Found in v, Cell Densities," <i>J. Cell. Biochem. 34</i> :13-2	JB6 Mouse Epidermal Cells: 22 (1987).		
	GA733-2," Proc. Natl. Acad. Sci					
	C 45	THOMPSON, et al., "Increased Fucosylati Cancer Letters 66:43-48 (1992).	ion and Other Carbohydrate Changes in Ha	ptoglobin in Ovarian Cancer,"		
	or Expression of Human					
	C 47	VLAHOU, et al., "Development of a Novel Proteomic Approach for the Detection of Transitional C the Bladder in Urine," Am. J. Pathol. 158:1491-1502 (2001).				
	C 48	WANG, et al., "Monitoring Gene Expressi 229:101-108 (1999).	ANG, et al., "Monitoring Gene Expression Profile Changes in Ovarian Carcinomas Using cDNA Micro 29:101-108 (1999). E, et al., "Identification and Validation of Urinary Biomarkers for Early Stage of Ovarian Cancer by Muroteomic Approaches," Proc. Am. Assoc. Cancer Res. 45:915 (abstract 3964 (2004)).			
	C 49					
	C 50	YIU, et al., "Prostasin, a Potential Serum Marker for the Early Detection of Ovarian Cancer," Proceedings of American Association for Cancer Research Annual 42:744 (2001).				
	C 51	YU, et al., "Molecular Cloning, Tissue-Specific Expression, and Cellular Localization of Human Prostasin mRN/Biol. Chem. 270:13483-13489 (1995).				
	C 52					
	C 53					
	C 54					
	C 55					
	C 56					
	C 57					
Examiner			Date Considered			